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OBJECTIVE — Diabetic large–nerve ﬁber dysfunction, as measured by vibration perception
threshold (VPT), predicts foot ulceration, amputation, and mortality. Thus, determination of
modiﬁable risk factors is of great clinical importance.
RESEARCH DESIGN AND METHODS — We assessed 1,407 patients with type 1
diabetes and a normal VPT participating in the EURODIAB Prospective Complications Study, at
baseline mean  SD age of 32.7  10.2 years with diabetes duration of 14.7  9.3 years and
follow-up of 7.3  0.6 years. VPT was measured using biothesiometry on the right big toe and
medial malleolus. An abnormal result was deﬁned as 2 SD from the predicted mean for the
patient s age.
RESULTS — An abnormal VPT was associated with an increased incidence of gangrene,
amputation, foot ulceration, leg bypass or angioplasty, and mortality (P  0.02). The incidence
of abnormal VPT was 24% over the 7.3-year follow-up. Duration of diabetes and A1C signiﬁ-
cantly inﬂuenced the incidence of abnormal VPT (P  0.0001). After correction for these,
established risk factors for cardiovascular disease (CVD), including male sex (P  0.0004),
hypertension (P  0.0001), total cholesterol (P  0.002), LDL cholesterol (P  0.01), smoking
(P  0.0001), weight (P  0.0001), and diabetes complications (retinopathy [P  0.0001],
nephropathy [P  0.01], and autonomic neuropathy [P  0.001]), were all found to be signif-
icant risk factors. A previous history of CVD doubled the incidence of abnormal VPT.
CONCLUSIONS — This prospective study indicates that cardiovascular risk factors predict
developmentoflarge-ﬁberdysfunction,whichmayaccountforthehighmortalityrateinpatients
with an abnormal VPT, and emphasizes the importance of early determination of VPT to detect
subclinical neuropathy and to address cardiovascular risk factors.
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C
hronic diabetic peripheral neuropa-
thy (DPN) is a slowly progressive
process, the pathogenesis of which
is poorly understood. However, we do
know that large-ﬁber dysfunction, as
measuredbyvibrationperceptionthresh-
old(VPT),predictsfootulceration,lower-
limb amputation, and mortality (1–3).
One consequence of these clinical com-
plications is a massive economic burden,
estimated in 2001 to be $10.9 billion in
the U.S. (4,5). Early in the natural history
of DPN, patients are usually asymptom-
atic. Thus, reliable identiﬁcation of in-
dividuals in the early stages of the
neuropathic process is required so that
morerigorousmodiﬁcationofriskfactors
and foot care education can be imple-
mented.Thebestmethodtoidentifysuch
patients is still a matter of some debate
(6–9).
In patients with type 2 diabetes, the
prevalence of an abnormal VPT has been
shown to be 11.4% (10), and the inci-
dence of an abnormal VPT was 19.9%
over a 12-year period (11). Some investi-
gatorshaveusedabsolutevaluesofVPTas
predictors of foot ulceration. In one
study,aVPT25Vwasassociatedwitha
sevenfoldincreaseinulcerrisk,compared
withthatofindividualswithaVPT15V
(12). Another study showed an incidence
of 7.2% of ﬁrst foot ulceration within 1
year in patients with a VPT 25 (13). In
addition, a cutoff of 25 V has been shown
to be a more sensitive way of detecting
patients at risk of foot ulceration than the
10-g monoﬁlament (14). Small-ﬁber dys-
function may be determined by measur-
ing thermal thresholds, but in terms of
discriminating between patients with and
without ulceration, it does not seem to
provide any additional value above mea-
surement of VPT (15).
Thus, ample evidence exists to high-
light the clinical importance of an abnor-
mally high VPT, but as yet there is little
evidence to identify the risk factors in-
volved in its development. Poor glycemic
control is associated with an abnormal
VPT even at diagnosis in patients with
type 2 diabetes (16). Evidence also sug-
gests that height is a determinant of VPT
(10,17).Importantly,VPTisknowntoin-
crease with age (18,19). The majority of
research regarding large-ﬁber dysfunc-
tion, as measured by VPT, has been con-
ductedinpatientswithtype2diabetes.In
this study, we have examined the inci-
dence of abnormal VPT in a large cohort
ofpatientswithtype1diabetestoidentify
possible modiﬁable risk factors.
RESEARCH DESIGN AND
METHODS— The EURODIAB Pro-
spective Complications Study recruited
3,250 patients (1,668 men and 1,582
women; aged [mean  SD] 32.7  10.2
years)withdurationofdiabetesof14.7
9.3 years. Subjects with type 1 diabetes
were randomly selected from 31 diabetes
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ria and methods have been described in
detail previously (20,21). The study was
approved by the ethics committee at each
center, and written informed consent was
provided by all subjects. All measure-
ments were obtained by trained physi-
cians following standardized procedures.
The baseline examinations were con-
ducted from 1989 to 1991, and a subse-
quent follow-up visit occurred between
1997 and 1999.
VPT was measured by centrally cali-
brated biothesiometers (Bio-Medical In-
strument Company, Newbury, OH).
Three readings on the right big toe and
right medial malleolus were obtained and
averaged. Results were classiﬁed accord-
ing to age-related criteria (19).
Neuropathy was deﬁned as the
presenceoftwoormoreofthefollowing
criteria: the presence of one or more
symptoms, the absence of two or more
reﬂexes of the ankle or knee tendons
(with reinforcement if necessary), an ab-
normal VPT value, and the presence of
cardiovascular autonomic neuropathy, as
described previously (21). Symptoms of
neuropathy were present if the subject
had experienced any of the following in
the preceding 6 months: “asleep” numb-
ness or “dead feeling” in the feet, a prick-
ling sensation in the feet, deep aching or
burning pains in the legs, unusual difﬁ-
culty in climbing stairs, difﬁculty with
bladder control, and nocturnal diarrhea.
Symptoms were assessed carefully to ex-
clude nondiabetic causes.
Blood samples, taken after an over-
night fast, if possible, were sent to central
laboratories. To compare the results with
those of the Diabetes Control and Com-
plications Trial, measured A1C values
were converted as reported previously
(22). Lipid measurements included total
cholesterol, HDL cholesterol, and triglyc-
erides. Levels of LDL cholesterol were
calculated.
Urinary albumin excretion rate was
obtained from a single 24-h urine collec-
tion. An albumin excretion rate between
20 and 200 g/min was deﬁned as mi-
croalbuminuria, whereas a rate of 200
g/min was deﬁned as macroalbumin-
uria. Diabetic retinopathy was determined
from centrally graded retinal photographs
and was classiﬁed as either nonproliferative
(background) or proliferative.
Cardiovascular disease (CVD) was
deﬁned as either a history of physician-
diagnosed CVD (e.g., previous myocar-
dial infarction, angina, coronary artery
bypass grafting, or stroke) or ischemic
changes on a 12-lead electrocardiogram
(classiﬁed by two observers according to
the Minnesota Code).
Of the 3,250 patients examined at
baseline,722hadabnormalVPT,whereas
1,407 with normal VPT were assessed at
follow-up (Fig. 1). Baseline investigations
and determination of VPT were repeated
after 7.3  0.6 years of follow-up.
Statistical analysis
The data were analyzed using the statisti-
calpackageSAS(version8).P0.05was
considered statistically signiﬁcant. For
variables that were continuous and nor-
mally distributed, a t test was used to
compare group means. If, however, the
variable had a skewed distribution, the
Mann-Whitney U test was used to com-
pare group medians and the variable was
log-transformed for any subsequent anal-
ysis. To compare group percentages, a 
2
test was used.
To assess which risk factors were as-
sociated with the development of VPT,
multiple logistic regression was used to
calculate odds ratios (ORs) adjusted for
A1C and duration. So that the ORs could
be compared, for each risk factor stan-
dardized ORs were calculated. For a
continuous variable, this was the OR as-
sociated with an increase of 1 SD, and for
a dichotomous variable, the reference
group was those patients without the re-
spectiveriskfactor.Similarly,multiplelo-
gistic regression was used to assess which
variables were associated with the inci-
dence of VPT while adjusting for all other
key risk factors.
To assess the effect of glycemic expo-
sure on the incidence of abnormal VPT,
linear regression was performed by the
centertocomparetheresultsofA1Cmea-
sured locally and centrally at the same
time, both at baseline. This comparison
provided a formula to convert locally mea-
sured A1C to the centralized assay at each
Figure 1—Patients examined for progression to abnormal VPT in the EURODIAB Study.
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that had been measured for each patient,
before the baseline visit, was calculated and
converted to the central measure.
A breakpoint or threshold effect for
the relation between A1C and progres-
siontoabnormalVPTwastestedbyatwo-
phase segmented weighted regression,
wheretwostraightlinesareﬁttedthrough
a series of deﬁned points. These points
were calculated by logistic regression ad-
justed for diabetes duration. This seg-
mented regression was compared with
the line of best ﬁt using weighted linear
regression. Logistic regression was also
used to test for a threshold.
RESULTS
Baseline characteristics according to
whether VPT was assessed at
follow-up
The baseline characteristics of the 1,407
patients examined in this study were
compared with those of patients who
qualiﬁed for follow-up (n  660) but did
not have a follow-up assessment. Those
who died or did not have VPT assessed at
follow-up had higher baseline A1C (8.5
vs.8.1%,P0.0001),waist-to-hipratios
(0.85 vs. 0.84, P  0.04), systolic blood
pressure (118 vs. 116 mmHg, P  0.05),
total cholesterol (5.35 vs. 5.21 mmol/l,
P  0.005), LDL cholesterol (3.37 vs.
3.27 mmol/l, P  0.05), and triglyceride
levels(0.96vs.0.87mmol/l,P0.0001).
In addition, they were more likely to
have a history of smoking (51 vs. 46%,
P  0.03) and proliferative retinopathy
(8 vs. 5%, P  0.02) and had lower von
Willebrand factor levels (1.09 vs. 1.14
units/ml, P  0.02).
Incidence of clinical outcomes
An abnormal VPT at baseline predicted
the incidence of several lower-limb com-
plications, i.e., foot ulcers (7.7 vs. 1.7%,
P  0.0001), leg bypass or angioplasty
(1.6 vs. 0.4%, P  0.02), gangrene (2.2
vs.0.6%,P0.004),amputation(2.4vs.
0.4%, P  0.0004), and, indeed, mortal-
ity (8.0 vs. 2.1%, P  0.0001).
Risk factors for the development of
an abnormal VPT
Of the 1,407 patients with normal a VPT
at baseline, an abnormal VPT developed
in 333 at follow-up, an incidence of
23.7%. Table 1 shows baseline character-
istics of the study group divided into
those who had an abnormal versus a nor-
malVPTatfollow-up.Patientswhodevel-
oped an abnormal VPT were signiﬁcantly
older (2.5 years), with longer duration of
diabetes(2.2years)andpoorerbloodglu-
cose control (A1C 0.6% higher) and were
taller (2 cm) at baseline than those pa-
tients who maintained a normal VPT.
Furthermore, patients who developed an
abnormal VPT had signiﬁcantly higher
levels of traditional cardiovascular risk
factors, i.e., male sex, history of smoking,
weight,BMI,waist-to-hipratio,hyperten-
sion, total cholesterol, LDL cholesterol,
triglycerides, history of CVD, and lower
HDL cholesterol levels. They were also
more likely to have established compli-
cations of diabetes, i.e., micro- or
microalbuminuria,higheralbuminexcre-
tion rates, any retinopathy, proliferative
retinopathy, and cardiac autonomic
neuropathy.
By adjusting for the established con-
founding factors of duration of diabetes
andA1C,riskfactorsforthedevelopment
of an abnormal VPT were determined us-
ingregressionanalysis(Table2).Virtually
all of the traditional risk factors of CVD
and established complications of diabetes
remainedsigniﬁcantlyassociatedwiththe
development of abnormal VPT, the only
exception being HDL cholesterol. The
risk factors with the highest ORs were
macroalbuminuria and proliferative reti-
nopathy, i.e., 2.48 and 2.17, respectively.
Furthermore, as expected, taller patients
were more likely to develop an abnormal
VPT, and this association also remained
statistically signiﬁcant after adjustment
for male sex (OR 1.38 [95% CI 1.16–
1.64], P  0.003).
Multivariate models
To examine independent associations be-
tween key risk factors and the incidence
ofabnormalVPT,multiplelogisticregres-
sion analysis was performed (Table 3). In
model 1, the analysis mutually adjusted
for the presence of all other risk factors. It
was found that duration of diabetes, A1C
Table 1—Baseline characteristics of 1,407 patients according to the incidence of abnormal
VPT
Progression to
abnormal VPT
Maintenance of
normal VPT P*
No. patients 333 1,074
Age (years) 33.4  10.2 30.9  8.8 0.0001
Duration of diabetes (years) 14.8  9.0 12.6  8.1 0.0001
Male sex (%) 56 46 0.001
History of smoking (%) 56 42 0.0001
Height (cm) 170  9 168  9 0.0004
Weight (kg) 70.1  10.8 65.5  10.1 0.0001
BMI (kg/m
2) 24.3  3.0 23.2  2.6 0.0001
Waist-to-hip ratio 0.85  0.11 0.83  0.10 0.0053
A1C (%) 8.6  2.0 8.0  1.8 0.0001
Insulin dose/kg body weight (IU) 0.67  0.21 0.69  0.22 0.1
Total cholesterol (mmol/l) 5.45  1.17 5.14  1.02 0.0001
LDL cholesterol (mmol/l) 3.48  1.05 3.20  0.91 0.0005
HDL cholesterol (mmol/l) 1.46  0.44 1.52  0.42 0.04
Triglycerides (mmol/l) 0.95 (0.54, 2.55) 0.84 (0.48, 2.06) 0.0001
Fibrinogen (g/l) 3.26  0.95 3.15  0.87 0.1
von Willebrand factor (units/ml) 1.25 (0.64, 2.32) 1.10 (0.54, 2.11) 0.0005
Systolic blood pressure (mmHg)† 117 (98, 152) 116 (96, 140) 0.06
Diastolic blood pressure (mmHg)† 75 (57, 93) 73 (57, 92) 0.09
Hypertension (%) 27 15 0.0001
History of CVD (%) 11 6 0.005
Albumin excretion rate (g/min) 12.6 (3.7, 447.4) 9.5 (3.2, 122.5) 0.0001
Macroalbuminuria (%) 9.5 3.3 0.0001
Micro- or macroalbuminuria (%) 33 22 0.0001
Any retinopathy (%) 52 33 0.0001
Proliferative retinopathy (%) 9 4 0.0001
Cardiac autonomic neuropathy (%) 39 28 0.0001
DataaremeansSDormedians(5thpercentile,95thpercentile)incasesofskeweddistributions.*Pvalues
arederivedfromStudent’sttestorfromaMann-WhitneyUtestincasesofskeweddistributionsand/orfrom
a 
2 test in cases of percentages. †The blood pressure data exclude patients who were undergoing antihy-
pertensive therapy.
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smoking,andpresenceofhypertensionat
baselineremainedsigniﬁcantlyassociated
with the incidence of abnormal VPT. The
relation between total cholesterol level
and the incidence of abnormal VPT did
not reach statistical signiﬁcance and nei-
ther did that of albumin excretion rate.
The strongest relation was with history of
smoking, which carried an OR of 1.71,
and the second strongest relation was
with hypertension with an OR of 1.65.
When complications of diabetes were
added to the model (model 2, Table 3)
duration of diabetes, as expected, was not
statistically signiﬁcant. A1C value, tri-
glyceride level, BMI, history of smoking,
and presence of hypertension at baseline
remained signiﬁcantly related to the inci-
dence of abnormal VPT. In addition, the
presenceofCVDatbaselinewasindepen-
dently related to the incidence of abnor-
malVPT,withanORof2.13.Therelation
between any retinopathy and abnormal
VPT was not signiﬁcant (P  0.1).
As expected, chronic glycemic expo-
sure was higher in the group who devel-
oped an abnormal VPT (A1C 0.3%
higher,P0.001).Whentheaboveanal-
yses were repeated using the adjusted
mean A1C, the ﬁndings were virtually
identical. Furthermore, when the rela-
tionship between A1C and progression to
abnormal VPT was tested, there was no
threshold effect.
CONCLUSIONS — Determination of
VPTusingabiothesiometerisaquickand
easy way of detecting large-ﬁber dysfunc-
tion and therefore identiﬁes patients at
risk of foot ulceration, lower-limb ampu-
tation, and mortality (1,2). During a pe-
riod of 12 years, the incidence of
abnormal VPT in patients with type 2 di-
abetes is estimated to be 19.9% (11). In
this larger prospective study of patients
with type 1 diabetes, we observed an in-
cidenceof23.7%over7.3yearsoffollow-
up. Apart from glycemic control and
duration of diabetes, we have demon-
strated that cardiovascular risk factors
such as hypertension, smoking, obesity,
elevated triglyceride levels, and the pres-
ence of CVD at baseline seem to predict
the development of abnormal VPT. The
patients who qualiﬁed for follow-up but
werenotassessedhadworseglycemicand
cardiovascular proﬁles, and hence our re-
sults may, if anything, have underesti-
mated the associations. The same
independent risk factors have previously
been shown to be related to newly diag-
nosedDPN(21).Bothhypertensionanda
history of smoking were strong risk fac-
tors for development of neuropathy and
an abnormal VPT. As expected, a higher
mean A1C value predicted the develop-
ment of an abnormal VPT, but no thresh-
old effect was identiﬁed. A similar
outcomewasfoundinapreviousstudyof
Table 2—Risk factors for the incidence of abnormal VPT after adjustment for A1C and
duration of diabetes
OR (95% CI) P
Male sex (%) 1.58 (1.23–2.04) 0.0004
History of smoking (%) 1.69 (1.31–2.18) 0.0001
Height (cm) 1.40 (1.22–1.59) 0.0001
Weight (kg) 1.64 (1.44–1.86) 0.0001
BMI (kg/m
2) 1.43 (1.26–1.62) 0.0001
Waist-to-hip ratio 1.17 (1.04–1.32) 0.009
Insulin dose/kg body weight (IU) 0.88 (0.77–0.99) 0.05
Total cholesterol (mmol/l) 1.22 (1.08–1.39) 0.002
LDL cholesterol (mmol/l) 1.22 (1.04–1.42) 0.01
HDL cholesterol (mmol/l) 0.90 (0.79–1.02) 0.10
Triglycerides (mmol/l) 1.35 (1.15–1.57) 0.002
von Willebrand factor (units/ml) 1.27 (1.08–1.51) 0.005
Hypertension (%) 1.88 (1.38–2.56) 0.0001
History of CVD (%) 1.62 (1.04–2.52) 0.03
Albumin excretion rate (g/min)* 1.29 (1.14–1.45) 0.0001
Macroalbuminuria (%) 2.48 (1.47–4.19) 0.0006
Micro- or macroalbuminuria (%) 1.44 (1.08–1.93) 0.01
Any retinopathy (%) 1.88 (1.36–2.61) 0.0001
Proliferative retinopathy (%) 2.17 (1.22–3.86) 0.008
Cardiac autonomic neuropathy (%) 1.58 (1.20–2.07) 0.001
Standardized ORs are expressed per SD increase in each continuous risk factor. ORs for dichotomous variables
have as a reference group those patients without the respective risk factor. *Log transformation was used.
Table 3—ORs for associations between key risk factors and the incidence of abnormal VPT with the use of two logistic-regression models
Variable
Model 1 Model 2
OR (95% CI) P OR (95% CI) P
Duration of diabetes (years) 1.21 (1.03–1.43) 0.02 1.12 (0.90–1.39) 0.3
A1C (%) 1.26 (1.06–1.49) 0.008 1.30 (1.07–1.68) 0.009
History of smoking (%) 1.71 (1.23–2.37) 0.001 1.85 (1.27–2.70) 0.01
Hypertension (%) 1.65 (1.08–2.50) 0.02 1.82 (1.12–2.94) 0.01
BMI (kg/m
2) 1.32 (1.12–1.56) 0.001 1.26 (1.04–1.53) 0.002
Total cholesterol (mmol/l) 1.06 (0.88–1.27) 0.6 0.94 (0.76–1.17) 0.6
Triglycerides (mmol/l) 1.21 (1.01–1.45) 0.04 1.27 (1.03–1.58) 0.03
Albumin excretion rate (g/min)* 1.15 (0.98–1.35) 0.09 1.20 (1.00–1.44) 0.05
History of CVD (%) 2.13 (1.10–4.12) 0.03
Any retinopathy (%) 1.44 (0.92–2.26) 0.1
Standardized ORs are expressed per SD increase in each continuous risk factor. ORs for dichotomous variables have as a reference group those patients without the
respectiveriskfactor.Model1wasmutuallyadjustedforallotherriskfactors.Model2wasmutuallyadjustedforallotherriskfactorsandcomplicationsofdiabetes.
*Log transformation was used.
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betic patients (9).
An abnormal VPT at baseline pre-
dicted the development of foot ulcers, leg
bypass or angioplasty, gangrene, amputa-
tion,andmortality.Thisﬁndingisconsis-
tent with previous studies (12,13). In a
generaldiabetesclinic,itisprobablymore
important to routinely use a test that is
highlysensitive,asopposedtohighlyspe-
ciﬁc, because the potential risk of DPN
being underdiagnosed is greater than the
risk of preventative measures being im-
plemented in patients with false-positive
results. Such measures include foot-care
education and more frequent follow-up,
for instance, in podiatrist-led neuropathy
clinics (23). Studies have shown that
measurement of VPT is more sensitive
than the 10-g monoﬁlament in assessing
footulcerrisk(14).Despitethisevidence,
at present monoﬁlaments are routinely
used in outpatient clinics. Although the
loss of the ability to feel a 10-g monoﬁla-
ment is known to predict ulceration (13),
it usually occurs at a late stage in the dis-
ease process. Conversely, an abnormal
VPT is often evident earlier in the natural
history of the disease (24). Another ad-
vantage of the VPT method is that it pro-
vides a quantitative result, and for each
unit increase, the risk of foot ulceration
increases (13).
Itiswellrecognizedthatpatientswith
diabetes have an increased risk for CVD.
Within the EURODIAB cohort, when the
cause of death was known, CVD was the
cause in 40% of subjects (25). This
present study shows that even in a young
cohort of patients with type 1 diabetes
(average age 32.7 years at baseline) an ab-
normal VPT identiﬁes a subset of patients
with adverse cardiovascular risk parame-
ters. This knowledge enables identiﬁcation
of those patients in need of more aggressive
treatment of their CVD risk factors. The all-
cause mortality rate of patients with an ab-
normal VPT at baseline was four times
higher than in those with a normal value (8
vs. 2% over 7.3 years of follow-up).
In summary, determination of an ab-
normal VPT is important for two reasons.
First,itidentiﬁesacohortofpatientswith
large-ﬁber dysfunction and its inherent
clinical risks, and second, it identiﬁes a
population with increased cardiovascular
risk. Therefore, intensive management of
cardiovascular risk factors could reduce
not only cardiovascular events but also
the clinical sequelae of neuropathy.
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